DEF: Actuate Therapeutics 2026 Annual Meeting Proxy Statement

Actuate Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for May 21, 2026, to vote on director elections and auditor ratification.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on May 21, 2026, at 11:00 a.m. EDT.
• Stockholders will vote on the election of two Class II directors: Aaron G.L. Fletcher, Ph.D. and Jason Keyes.
• Stockholders will vote on the ratification of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Only stockholders of record as of March 24, 2026, are entitled to vote.
• The company has 23,704,691 shares of common stock outstanding as of the record date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing. The document focuses on standard corporate governance and does not contain new material financial results or strategic pivots.

Positives

• The company successfully raised over $25 million in gross proceeds from equity financings in 2025, triggering performance-based compensation adjustments for executive officers.
• The board maintains a majority of independent directors as defined by Nasdaq rules.
• The company has adopted a compensation recovery (clawback) policy compliant with Nasdaq Listing Rules.
• The company has implemented a virtual meeting format to facilitate broader stockholder participation.

Negatives

• The company's board is classified into three classes with staggered terms, which may delay or prevent a change in control.
• Directors can only be removed for cause by the affirmative vote of at least two-thirds of outstanding voting stock.
• The company has a history of issuing convertible promissory notes and preferred stock with complex conversion terms, which can lead to significant dilution.

Risks

• The company's reliance on specific venture capital and equity-affiliated funds for financing creates concentration risk.
• The potential for future dilution remains high due to outstanding warrants and equity incentive plans.
• The company operates in the highly competitive and capital-intensive biotechnology industry, which carries inherent clinical and regulatory risks.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.

Future Outlook

The company continues to focus on its clinical-stage biopharmaceutical operations and expects to hold its next annual meeting in 2027. Management remains focused on strategic milestones and potential licensing or capital-raising transactions through 2026.

Management Comments

• The Board unanimously recommends a vote FOR the election of all director nominees.
• The Board unanimously recommends a vote FOR the ratification of the appointment of Crowe LLP as the independent registered public accounting firm.

Industry Context

StockSavvy.ai notes that Actuate Therapeutics is following standard corporate governance practices for a recently public clinical-stage biotech company, including the use of a classified board and virtual-only shareholder meetings to manage costs and logistics.

Comparison to Industry Standards

• The use of a classified board is common among small-cap biotech companies to provide stability during clinical development phases.
• The executive compensation structure, including performance-based equity grants tied to financing milestones, is standard for the sector.
• The transition to virtual-only meetings is an industry-wide trend to increase accessibility for retail investors.

Corporate Governance

Related Party Transactions

• The company has extensive historical and ongoing financing relationships with Bios Equity Affiliated Funds and Kairos Venture Affiliated Funds, which are represented on the board.
• The company has entered into indemnification agreements with all directors and executive officers.

Stakeholder Impact

• Shareholders are requested to vote on director elections and auditor ratification.
• The company's reliance on specific venture capital firms may influence strategic direction and capital structure decisions.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on May 21, 2026.
• File the final voting results in a Form 8-K within four business days following the meeting.
• Prepare for the 2027 Annual Meeting, with stockholder proposals due by December 9, 2026.

Key Dates

Keywords

Actuate Therapeutics, Proxy Statement, Biotechnology, Corporate Governance, Executive Compensation, SEC Filing, Annual Meeting